Clinical Trials

Gilead announces data from two studies supporting further development of investigational HIV-1 capsid inhibitor GS-6207

Gilead Sciences has announced findings from two studies that support the further development of GS-6207, a novel, selective, first-in-class inhibitor of HIV-1 capsid function, for potential future use as part of long-acting HIV combination therapy.

ViiV Healthcare reports positive data for two phase 3 HIV trials of cabotegravir, rilpivirine regimen

ViiV Healthcare presented comprehensive 48-week data from the ATLAS (Antiretroviral Therapy as Long-Acting Suppression) and FLAIR (First Long-Acting Injectable Regimen) pivotal phase III studies of the novel, investigational, long-acting regimen of cabotegravir and rilpivirine.

HIV remission achieved in second patient

A second person has experienced sustained remission from HIV-1 after ceasing treatment, reports a paper led by UCL and Imperial College London.

Novo Nordisk’s Ozempic meets primary endpoint in Sustain 9 diabetes trial

Novo Nordisk’s Ozempic (semaglutide), in combination to SGLT-2 inhibitor (SGLT-2i) therapy, met the primary endpoint in a phase 3 trial in patients with type 2 diabetes.

Novartis data confirm rapid response and high efficacy of Cosentyx in psoriasis patients for first time in China

Novartis announced new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosentyx (secukinumab).

Verona’s ensifentrine DPI formulation succeeds in part 1 of COPD trial

Verona Pharma said that the first part of a two-part phase 2 trial of ensifentrine in a dry powder inhaler (DPI) formulation for the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD) has yielded positive interim efficacy and safety data.

Shield Therapeutics’ Feraccru meets endpoints in anaemia trial

Shield Therapeutics said that its oral ferric iron therapy Feraccru proved to be non-inferior to Ferinject (ferric carboxymaltose or FCM), a widely used intravenously delivered iron replacement therapy, in the AEGIS-H2H non-inferiority study.

Horizon’s phase 3 trial for Teprotumumab in active thyroid eye disease meets primary endpoint

Horizon Pharma plc (Nasdaq: HZNP) today announced topline results from its Phase 3 confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease (TED).

GDNF trial yields promising results for treatment of Parkinson’s Disease

A clinical trial held in the UK in patients with Parkinson’s Disease showed that it could be possible to restore damaged neurons by boosting the levels of a naturally-occurring protein called Glial Cell Line Derived Neurotrophic Factor (GDNF).